Mitapivat
Pyruvate kinase activator / Potent (AC50 = 29 nM PKR; 37 nM PKM2; 33 nM PKL) allosteric activator of pyruvate kinase.1 In clinical use for the treatment of hemolytic anemia2 and a potential agent for the treatment for ß-thalassemia3 and sickle cell anemia4.
Biochemicals & reagents
1260075-17-9
AG-348
1) Kung et al. (2017), AG-348 enhances pyruvate kinase activity in red blood cells from patients with pyruvate kinase deficiency; Blood, 130 1347 2) Rab et al. (2021), AG-348 (mitapivat), an allosteric activator of red blood cell pyruvate kinase, increases enzymatic activity, protein stability, and adenosine triphosphate levels over a broad range of PKLR genotypes; Haematologica, 106 238 3) Matte et al. (2021), The pyruvate kinase activator mitapivat reduces hemolysis and improves anemia in a ß-thalassemia mouse model; J. Clin. Invest., 131 e144206 4) Rab et al. (2021), Decreased activity and stability of pyruvate kinase in sickle cell disease: a novel target for mitapivat therapy; Blood, 137 2997
-20°C
TARGET: Kinase -- PATHWAY: Mitochondrial function -- RESEARCH AREA: Oxidative stress -- DISEASE AREA: Cancer